在患有类风湿性关节炎的患者中治疗rituximab的经验教训
Leticia Garcia-Montoya1, Catalina Villota-Eraso2, Md Yuzaiful Md Yusof1
1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK; National Institute for Health Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
The Lancet. Rheumatology
|January 26, 2024
概括
在类风湿性关节炎中,Rituximab完全减少B细胞预测了反应,但反应的丧失通常是可逆的. 诸如低预处理血芽细胞和特定抗体等因素预测成功.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 包括Rituximab在内的B细胞枯竭疗法用于类风湿性关节炎.
- 完整的B细胞枯竭与临床反应和持续治疗有关.
研究的目的:
- 为了确定B细胞完全枯竭的预测因素和对rituximab的临床反应.
- 调查Rituximab不响应的可逆性和重新治疗的有效性.
- 探索使用降低剂量利图西马布的使用及其相关风险.
主要方法:
- 分析患者数据以确定预测B细胞枯竭和反应的因素.
- 在Rituximab治疗和再治疗后观察患者的结果.
- 监测不良事件,包括输液反应和感染风险.
主要成果:
- 在Rituximab后完全减少B细胞与临床反应和长期治疗维持相关.
- 预测反应的预测因素包括治疗前低血质,同时服用DMARDs,非吸烟者身份,ACPA/RF的存在和低干扰素特征.
- 一半的患者最终失去了反应,但四分之三的患者在重新治疗后恢复了反应,表明可逆性.
- 减少rituximab剂量可能适用于维持疗法,特别是对于具有不良事件或高感染风险的患者.
- 与输液相关的反应很常见;由于低度的感染风险,监测IgG至关重要.
结论:
- 完整的B细胞枯竭是利图西马布在类风湿性关节炎中有效性的关键指标.
- 利图西马布不响应可能是可逆的,支持重新治疗策略.
- 仔细的患者选择和监测对于优化利图西马布治疗和管理风险至关重要.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
01:17Drugs Used in Lower Respiratory Disorders: Overview
442
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
442